Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product candidate, in combination with Alimta(R) (pemetrexed) and in combination with Taxotere(R) (docetaxel) as a second-line treatment for patients with non-small cell lung cancer (NSCLC) who failed at least one platinum-based chemotherapy regimen. The results were presented today at the Eighth International Lung Cancer Congress in Wailea, Hawaii.

The first ongoing study is evaluating Xcytrin plus Alimta and has enrolled 27 patients of which 20 are evaluable for response at this time. Patients are receiving 15mg/kg Xcytrin with a standard dose of Alimta and treatment is repeated every 21 days. Seventeen patients (85%) receiving Xcytrin and Alimta have achieved stabilization of their tumors, with 10 of the 17 still on treatment for up to nine cycles. The median survival time and median time to progression have not been reached, with estimated actuarial survival of 69% at 12 months. Patients still on treatment remain under evaluation for tumor response. The most common severe (Grade 3 or higher) side effects were asthenia (10.3%), pneumonia (10.3%), thrombocytopenia (10.3%), and neutropenia (6.9%).

The other ongoing study is evaluating Xcytrin plus Taxotere and has enrolled 24 patients of which 14 are evaluable for response at this time. Patients are given 15mg/kg Xcytrin with a standard dose of Taxotere and treatment is repeated every 21 days. Thirteen patients (87%) receiving Xcytrin and Taxotere have achieved stabilization of their tumors, with four still on treatment. The median survival time is 8.2 months and the median time to progression is 8.7 months. Patients still on treatment remain under evaluation for
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle ... makers of medical devices. As part of its ... in EMEA concentrates on the EMEA medical device ...
(Date:8/20/2014)... Reportlinker.com announces that ... its catalogue: EMR 2014: The Market ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously examined ... for nearly a decade, and each year we ... report has become the industry standard, oft-quoted by ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8
... Aug. 25, 2011 BioRestorative Therapies, Inc. ... into a Tangible Property License Agreement with the University ... Therapies to obtain adipose (fat) tissue that will be ... ThermoStem Program , which is an adult derived ...
... ePharmaSolutions announced the successful deployment of its Enterprise ... global pharmaceutical company on more than 900 studies to ... September 2011. Clinical Trial Portals help streamline ... sites and third party vendors by providing a common ...
Cached Medicine Technology:BioRestorative Therapies Signs License Agreement With University of Utah to Obtain Adipose (Fat) Tissue for its ThermoStem Program to Treat Obesity and Metabolic Disorders 2ePharmaSolutions Announces the Deployment of its Enterprise Clinical Trial Portal for Two Global Biopharmaceutical Companies 2
(Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
(Date:8/20/2014)... NEW YORK -- The most common cause of endophthalmitis, ... trauma, eye surgery, and eye injections, are the well-known ... bacterial strains, according to a study published in the ... a review of 25 years of cases at New ... , The new study found that gram-positive bacteria, ...
(Date:8/20/2014)... HealthDay Reporter TUESDAY, Aug. 19, 2014 ... baby,s immune system is twice as common as once believed, ... This is the first evaluation of the effect of ... severe combined immunodeficiency (SCID), or "Bubble Boy" disease, the researchers ... the boy in the bubble, who was born without an ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
... similar results, , , WEDNESDAY, Feb. 25 (HealthDay News) -- If ... type of diet plan you choose. What really matters is that ... 26 issue of the New England Journal of Medicine ... of fat, protein and carbohydrates -- and found that any eating ...
... Millstone Medical Outsourcing announced today the opening of ... The company acquired the new 30,000 square foot facility ... and clean room services. The company will continue ... foreseeable future. In addition to the two Fall ...
... hormones, not HRT, researchers note , , WEDNESDAY, Feb. 25 ... help protect her from developing Parkinson,s disease, a new ... (the time from first menstruation to menopause) have a ... findings released Wednesday and scheduled to be presented at ...
... Other Health Insurers Illegally Deny Treatment to Autistic Children, ... of autistic children and their families joined Consumer Watchdog ... health insurance companies that are scheming to avoid paying ... , , Consumer Watchdog released a letter ...
... United Airlines customer service representatives, ramp employees, flight ... at Children,s Memorial Hospital and University of ... United Airlines employees today delivered teddy bears to ... and University of Chicago Comer Children,s ...
... to ,Protect the Safety Net, , WASHINGTON, Feb. 25 ... long-term care advocacy organizations, the American Health Care Association ... today praised and thanked U.S. Representatives Earl Pomeroy (D-ND), ... Brown-Waite (R-FL) for sending a new letter to President ...
Cached Medicine News:Health News:Want to Lose Weight? Just Eat Less, Diet Study Suggests 2Health News:Want to Lose Weight? Just Eat Less, Diet Study Suggests 3Health News:Millstone Medical Outsourcing Opens New Facility to Provide Additional Capacity for Advanced Inspection, Clean Room Operations 2Health News:Hormones May Help Shield Women from Parkinson's 2Health News:Parents of Autistic Children Fight Back -- Warn HMO Regulator Against Siding With Insurers Refusing to Pay for Treatment 2Health News:Parents of Autistic Children Fight Back -- Warn HMO Regulator Against Siding With Insurers Refusing to Pay for Treatment 3Health News:Delivering Bear-y Big Smiles and Millions of Miles 2Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 2Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: